4.4 Review

Alpers-Huttenlocher Syndrome

期刊

PEDIATRIC NEUROLOGY
卷 48, 期 3, 页码 167-178

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.pediatrneurol.2012.09.014

关键词

-

资金

  1. National Institutes of Health through National Institute of Environmental Health [ES 065078]
  2. National Institutes of Health [U54NS078059-01]
  3. Mitochondrial Research Guild at Seattle Children's Hospital
  4. University of California at San Diego
  5. Wright Foundation
  6. Lennox Foundation
  7. Jane Botsford-Johnson Foundation
  8. Hailey's Wish Foundation

向作者/读者索取更多资源

Alpers-Huttenlocher syndrome is an uncommon mitochondrial disease most often associated with mutations in the mitochondrial DNA replicase, polymerase-gamma. Alterations in enzyme activity result in reduced levels or deletions in mitochondrial DNA. Phenotypic manifestations occur when the functional content of mitochondrial DNA reaches a critical nadir. The tempo of disease progression and onset varies among patients, even in identical genotypes. The classic clinical triad of seizures, liver degeneration, and progressive developmental regression helps define the disorder, but a wide range of clinical expression occurs. The majority of patients are healthy before disease onset, and seizures herald the disorder in most patients. Seizures can rapidly progress to medical intractability, with frequent episodes of epilepsia partialis continua or status epilepticus. Liver involvement may precede or occur after seizure onset. Regardless, eventual liver failure is common. Both the tempo of disease progression and range of organ involvement vary from patient to patient, and are only partly explained by pathogenic effects of genetic mutations. Diagnosis involves the constellation of organ involvement, not the sequence of signs. This disorder is relentlessly progressive and ultimately fatal. (C) 2013 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据